XML 60 R45.htm IDEA: XBRL DOCUMENT v3.25.4
Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Nov. 20, 2025
USD ($)
Aug. 13, 2025
USD ($)
shares
Feb. 24, 2025
USD ($)
Feb. 14, 2025
USD ($)
Feb. 07, 2025
USD ($)
Nov. 25, 2024
USD ($)
obligation
program
Nov. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
Aug. 31, 2025
USD ($)
shares
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Treasury stock value               $ 53,193   $ 53,193 $ 53,193  
Revenue                   264,033   $ 2,500
Accounts receivable               6,824   218,871 6,824  
Contract assets               0   9,827 0 $ 0
Sarepta                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue                   229,500    
Accounts receivable                   218,400    
Contract assets                   $ 9,800    
Sarepta | Sarepta Collaboration Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of performance obligations | obligation           17            
Upfront payment   $ 50,000 $ 500,000 $ 500,000         $ 50,000   50,000  
Proceeds from sale of stock         $ 325,000              
Equity premium         $ 83,600              
Annual fees           $ 250,000            
Annual installment           $ 50,000            
Annual installments period           5 years            
Total transaction price           $ 904,900            
Fixed consideration           833,600            
Variable consideration           $ 71,200            
Development milestone payments $ 200,000           $ 200,000 $ 100,000 100,000      
Value of stock repurchased   $ 50,000             $ 50,000   $ 50,000  
Number of collaboration programs | program           13            
Collaboration agreement termination notice period prior to any regulatory approval of a licensed product           30 days            
Common stock repurchased (in shares) | shares   2,660,989             2,660,989      
Treasury stock value   $ 53,200             $ 53,200      
Gain on settlement of treasury stock   $ 3,200             $ 3,200      
Sarepta | Sarepta Collaboration Agreement | Maximum                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of new target programs | program           6            
Regulatory milestone payments           $ 180,000            
Sales-related milestone payments           700,000            
Sarepta | Sarepta Collaboration Agreement | Minimum                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Regulatory milestone payments           110,000            
Sales-related milestone payments           $ 500,000